Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Protocol For A Double-Blind, Randomized, Placebo-Controlled Comparison Of The Efficacy, Safety, And Tolerability Of Bextra® (Valdecoxib) 20 Mg Twice Daily, Bextra® 40 Mg Once Daily, And Placebo In The Symptomatic Treatment Of Subjects With Pharyngitis

NCT00647829 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00647829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00647829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Protocol For A Double-Blind, Randomized, Placebo-Controlled Comparison Of The Efficacy, Safety, And Tolerability Of Bextra® (Valdecoxib) 20 Mg Twice Daily, Bextra® 40 Mg Once Daily, And Placebo In The Symptomatic Treatment Of Subjects With Pharyngitis
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2003
Completion date
December 31, 2003
Enrollment
197 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pharyngitis